RecruitingPhase 2NCT06211114
Study to Evaluate the Efficacy and Safety of Immunotherapy With Axitinib in Advanced Collecting Duct Carcinoma
Studying Collecting duct carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Peking University Cancer Hospital & Institute
- Principal Investigator
- Xinan Sheng, MD.Peking University Cancer Hospital & Institute
- Intervention
- PD-(L)1 inhibitor(drug)
- Enrollment
- 30 enrolled
- Eligibility
- 18-80 years · All sexes
- Timeline
- 2024 – 2027
Study locations (2)
- Department of Genitourinary Oncology, Peking University Cancer Hospital & Institute, Beijing, Beijing Municipality, China
- Beijing Cancer Hospital, Beijing, Beijing Municipality, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06211114 on ClinicalTrials.govOther trials for Collecting duct carcinoma
Additional recruiting or active studies for the same condition.